| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 479,171 | 370,036 | 358,393 | 396,864 |
| Accounts receivable, net | 345,538 | 214,131 | 235,246 | 279,011 |
| Inventory | 122,819 | 121,000 | 82,468 | 121,058 |
| Prepaid assets | 31,560 | 29,171 | 37,104 | 23,809 |
| Restricted cash | 1,430 | 1,430 | 1,434 | 1,373 |
| Other current assets | 10,158 | 19,842 | 13,073 | 11,782 |
| Total current assets | 990,676 | 755,610 | 727,718 | 833,897 |
| Right-of-use assets | 19,720 | 14,637 | 15,251 | 17,060 |
| Property and equipment, net | 1,927 | 2,117 | 2,514 | 3,379 |
| Long-term inventory | 40,909 | 48,128 | 60,652 | 46,080 |
| Other assets | 5,491 | 898 | 1,150 | 1,450 |
| Total assets | 1,058,723 | 821,390 | 807,285 | 901,866 |
| Accounts payable | 38,602 | 54,241 | 55,287 | 42,730 |
| Accrued expenses | 140,322 | 138,999 | 116,146 | 139,835 |
| Convertible senior notes | 93,581 | - | - | - |
| Current portion of lease liabilities | 7,022 | 7,419 | 6,944 | 6,792 |
| Deferred revenue | - | - | - | 1,903 |
| Total current liabilities | 279,527 | 200,659 | 178,377 | 191,260 |
| Long-term credit facility | 361,091 | 360,535 | 360,001 | 358,982 |
| Convertible senior notes | 0 | 93,500 | 93,421 | 93,263 |
| Lease liabilities | 13,680 | 8,313 | 9,186 | 11,411 |
| Other liabilities | 3,257 | 2,078 | 2,084 | 9,829 |
| Total liabilities | 657,555 | 665,085 | 643,069 | 664,745 |
| Common stock, 0.0001 par value 200,000 shares authorized at september 30, 2025 and december 31, 2024 126,500 shares issued and outstanding at september 30, 2025, and 124,495 shares issued and outstanding at december 31, 2024 | 12 | 12 | 12 | 12 |
| Additional paid-in capital | 3,357,583 | 3,328,604 | 3,294,849 | 3,239,262 |
| Accumulated other comprehensive loss | -2,400 | -2,569 | -3,054 | -3,140 |
| Accumulated deficit | -2,954,027 | -3,169,742 | -3,127,591 | -2,999,013 |
| Total stockholders' equity | 401,168 | 156,305 | 164,216 | 237,121 |
| Total liabilities and stockholders' equity | 1,058,723 | 821,390 | 807,285 | 901,866 |
Apellis Pharmaceuticals, Inc. (APLS)
Apellis Pharmaceuticals, Inc. (APLS)